scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1002123350 |
P356 | DOI | 10.1186/1476-4598-13-12 |
P8608 | Fatcat ID | release_q4pjdlmy2vhvpbtntlroai6h2q |
P932 | PMC publication ID | 3932516 |
P698 | PubMed publication ID | 24461075 |
P5875 | ResearchGate publication ID | 259915920 |
P50 | author | Hala Gali-Muhtasib | Q51113283 |
Kazem Zibara | Q55293505 | ||
P2093 | author name string | Marwan El-Sabban | |
Makhluf J Haddadin | |||
Hala Gali-Muhtasib | |||
Sally El-Sitt | |||
Khaled Ghattass | |||
Saide Rayes | |||
P2860 | cites work | Direct regulation of TWIST by HIF-1alpha promotes metastasis | Q24316939 |
Targeting HIF-1 for cancer therapy | Q27860504 | ||
Metastasis: a question of life or death | Q28242176 | ||
Differentiation arrest by hypoxia | Q42797711 | ||
Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation. | Q44832487 | ||
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). | Q45206507 | ||
Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer | Q46944975 | ||
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity | Q59617803 | ||
Growth-related changes of oxygen consumption rates of tumor cells grown in vitro and in vivo | Q69936647 | ||
Exploiting tumour hypoxia in cancer treatment | Q28264146 | ||
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group | Q28282755 | ||
Targeting hypoxia in cancer therapy | Q29615491 | ||
Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion | Q33630843 | ||
Suppression of Hypoxia-Inducible Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the mTORC1/4E-BP1 Pathway | Q33749777 | ||
HIF-1 and mechanisms of hypoxia sensing | Q34180645 | ||
Conversion of stationary to invasive tumor initiating cells (TICs): role of hypoxia in membrane type 1-matrix metalloproteinase (MT1-MMP) trafficking | Q34297111 | ||
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis | Q34479984 | ||
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus | Q34532986 | ||
Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells | Q35263224 | ||
Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells | Q35589210 | ||
Gene expression and hypoxia in breast cancer | Q35614451 | ||
Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis | Q36220525 | ||
Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer | Q36393103 | ||
Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. | Q36502589 | ||
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. | Q36732878 | ||
Hypoxia-driven selection of the metastatic phenotype | Q36801461 | ||
Hypoxia and metastasis in breast cancer. | Q36808477 | ||
Bioreductive drugs: from concept to clinic | Q36812319 | ||
Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation | Q36994805 | ||
The tumor microenvironment and metastatic disease | Q37187529 | ||
The radiosensitizer 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide induces DNA damage in EMT-6 mammary carcinoma cells | Q37276709 | ||
Targeting tumour hypoxia in breast cancer | Q37319813 | ||
Cancer stem cells, hypoxia and metastasis | Q37403294 | ||
Cancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspective | Q37706840 | ||
Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010). | Q37826426 | ||
Targeting hypoxia for sensitization of tumors to radio- and chemotherapy | Q38107961 | ||
Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics | Q38318356 | ||
Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells | Q39186478 | ||
The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression | Q39369979 | ||
Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21 | Q39631718 | ||
The novel hypoxic cell radiosensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancer | Q39944749 | ||
Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cells | Q40531329 | ||
Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents | Q40740278 | ||
Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. | Q40813759 | ||
Multidrug resistance in breast cancer: from in vitro models to clinical studies | Q42695791 | ||
P921 | main subject | hypoxia | Q105688 |
cancer metastasis | Q120912394 | ||
P304 | page(s) | 12 | |
P577 | publication date | 2014-01-24 | |
P1433 | published in | Molecular Cancer | Q15724585 |
P1476 | title | The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway | |
P478 | volume | 13 |
Q38944439 | Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines. |
Q93358186 | Effects of VEGFR1+ hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells |
Q64941626 | Genotoxic risk of quinocetone and its possible mechanism in in vitro studies. |
Q36026944 | Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function |
Q28084024 | Mechanisms involved in breast cancer liver metastasis |
Q47106685 | Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones |
Q91671487 | Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database |
Q55353906 | Organotropism: new insights into molecular mechanisms of breast cancer metastasis. |
Q26752388 | Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions |
Q47938041 | Synthesis and Evaluation of New Quinoxaline Derivatives of Dehydroabietic Acid as Potential Antitumor Agents |
Q92945770 | Synthesis and Properties of Quinoxaline-Containing Benzoxazines and Polybenzoxazines |
Q38759912 | The photoprotective effects of 2-benzoyl-3-phenylquinoxaline 1,4-dioxide against UVB-induced damage in HaCaT cells |
Q59801804 | Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells |
Search more.